Pfizer Inc. (PFE) Shares Bought by Insight 2811 Inc.
Insight 2811 Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 8.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,207 shares of the biopharmaceutical company’s stock after purchasing an additional 2,972 shares during the period. Pfizer comprises about 1.0% of Insight 2811 Inc.’s holdings, making the stock its 15th largest position. Insight 2811 Inc.’s holdings in Pfizer were worth $1,293,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Vanguard Group Inc. grew its holdings in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Pfizer by 0.9% during the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after buying an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Pfizer by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after buying an additional 2,028,313 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Pfizer by 3.2% during the third quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after buying an additional 1,085,437 shares during the last quarter. Finally, LSV Asset Management grew its holdings in shares of Pfizer by 0.6% during the second quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock worth $1,117,726,000 after buying an additional 199,100 shares during the last quarter. Institutional investors and hedge funds own 69.75% of the company’s stock.
PFE has been the topic of a number of research reports. BMO Capital Markets reissued a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Barclays set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. Pfizer currently has an average rating of “Buy” and an average price target of $38.77.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the previous year, the company earned $0.61 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. equities research analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 79.01%.
Pfizer announced that its Board of Directors has approved a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock worth $1,065,220 in the last ninety days. 0.06% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/pfizer-inc-pfe-shares-bought-by-insight-2811-inc/1791545.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.